Sanofi and Johnson & Johnson’s E. coli vaccine candidate failed to prevent invasive E. coli disease effectively.

With no fanfare after 89 reported sick, the FDA has closed its investigation into a romaine lettuce E. coli outbreak without ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over ...

Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...

Johnson & Johnson and Sanofi said that while the vaccine showed no safety concerns, it did not meet the necessary ...

Due to the discontinuation, Sanofi said that it has recorded an impairment charge before tax of $250 million in the Q4 2024 ...

Sanofi and J&J halted a phase 3 E. coli vaccine trial due to insufficient efficacy. Sanofi's Q4 2024 IFRS EPS dropped by ...

Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing ...

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, ...

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical studyIndependent interim analysis of the E.mbrace phase 3 study finds that ...

The Food and Drug Administration is continuing to investigate several outbreaks of foodborne illnesses and has closed its ...